On-Demand CME Videos
Take the Challenge to Manage Moderate-to-Severe Psoriasis From Head-to-Toe: CME Satellite Symposium - Online CME Activity
What site is associated with the greatest risk for the development of psoriatic arthritis?
To find out the answer, click below to start the activity!
This activity is supported by an educational grant from Lilly.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
July 18, 2023
July 18, 2024
At the completion of this activity, participants should be better able to:
Identify the relationship between psoriasis, psoriatic arthritis and biologics
Describe the role of IL-17 inhibitors for the management of moderate-to-severe plaque psoriasis in challenging body areas such as, nails, scalp, genitals, palms, and soles of the feet
Recognize patients who would benefit from IL-17 inhibitors for the management of moderate-to-severe plaque psoriasis in challenging body areas
Discuss how PAs and NPs can work in a multidisciplinary team to manage patients with moderate-to-severe plaque psoriasis in challenging body areas
This activity has been designed for dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Brad Glick, DO, MPH
Program Director, Dermatology Residency
Larkin Community Hospital Palm Springs Campus
Benjamin Lockshin, MD
EVP of Strategic Initiatives
Director of the Clinical Trials Center
US Dermatology Partners
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Ownership interest: Top MD stock
Grant/Research Support: Abbvie, Eli Lilly, Celgene, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Pfizer, Leo, Arcutis, Dermavant
Consultant: AbbVie, Eli Lilly, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Dermavant, Arcutis, Leo
Speakers’ Bureau or Honoraria: Abbvie, Eli Lilly, Regeneron, Sanofi Genzyme, Dermavant, Arcutis, Leo
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.